Semaglutide vs Tirzepatide: Which Works Best?

Medically reviewed by Jacquelyn McDowell, FNP-C, Medical Director, and Courtney Strocky, NP. Last reviewed November 11, 2026.

The short answer: in clinical trials, tirzepatide's dual-receptor mechanism produces more weight loss on average than semaglutide. Semaglutide has been in broad clinical use longer and is generally well tolerated. Which one suits you depends on your goals, your medical history, and how your body responds. Both need ongoing use to keep the results.

Semaglutide and Tirzepatide at a Glance

Figures are for the brand-name drugs, from their FDA labels and the trials linked below.

What Is the Key Difference Between Semaglutide and Tirzepatide?

Semaglutide activates one receptor, GLP-1 (glucagon-like peptide-1). Tirzepatide activates two at once, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), which produced stronger metabolic effects and more weight loss in clinical trials.

GLP-1 is an incretin hormone. It reduces appetite, slows how quickly your stomach empties, and prompts insulin release when you eat. Semaglutide is a GLP-1 receptor agonist, so it mimics that hormone through a single pathway. The FDA first approved it for type 2 diabetes in 2017 and then, in June 2021, for weight management as Wegovy, at a higher weekly dose of 2.4 mg (Wegovy prescribing information).

Tirzepatide adds the GIP receptor. GIP works alongside GLP-1 on insulin sensitivity and fat metabolism. Researchers think this added action helps explain why tirzepatide produced more weight loss in head-to-head trials. Tirzepatide was FDA-approved for weight management in November 2023 as Zepbound, after its 2022 approval for type 2 diabetes.

Both are once-weekly injections under the skin. Both start at a low dose and increase over several weeks so your body can adjust. Both are long-term treatments, and results last only as long as you keep taking them.

Which Treatment Delivers Greater Weight Loss?

Tirzepatide produced more weight loss in clinical trials. In the SURMOUNT-1 phase 3 trial published in the New England Journal of Medicine, participants lost an average of 15.0% of their body weight over 72 weeks on the 5 mg dose, 19.5% on 10 mg, and 20.9% on the highest 15 mg dose. Semaglutide's pivotal STEP 1 trial, also published in the NEJM, showed an average loss of 14.9% of body weight over 68 weeks at the 2.4 mg dose.

Those were separate trials, so comparing them directly has limits. The two drugs have since been compared head to head. In the SURMOUNT-5 trial, published in the NEJM in 2025, 751 adults with obesity and without type 2 diabetes were randomly assigned to one drug or the other at the highest dose they could tolerate. At 72 weeks, average weight loss was 20.2% on tirzepatide and 13.7% on semaglutide. A 2025 real-world study of insurance records for nearly 10,000 patients without type 2 diabetes found a smaller gap: 16.5% on tirzepatide and 14.1% on semaglutide after one year.

Some context for these numbers. They are averages, and results vary from person to person. In STEP 1, 86.4% of people on semaglutide lost at least 5% of their body weight, which means about 1 in 7 lost less. In both trial programs, most of the loss came in the first year before weight leveled off, and continued treatment held that level. On both medications, stopping leads to significant weight regain.

Tirzepatide gives meaningfully more weight loss on average. Semaglutide's results are still clinically significant, and more long-term evidence stands behind them.

How Do Side Effects and Tolerability Compare?

The two medications have similar digestive side effects. In SURMOUNT-5, the head-to-head trial, the most common side effects in both groups were digestive, most were mild to moderate, and they mostly happened while the dose was being increased.

The most common side effects for both are nausea, vomiting, diarrhea, constipation, abdominal discomfort, and fatigue.

Both medications slow gastric emptying as part of how they work. Neither is recommended for people with severe gastrointestinal disease, including severe gastroparesis, so tell your prescribing provider about any digestive condition you have.

Nausea and vomiting early in treatment can lead to dehydration and electrolyte imbalance if no one is keeping an eye on it. A well-run program builds in hydration guidance and dietary adjustments for the first weeks.

Animal studies showed thyroid C-cell tumors with GLP-1 agonists. For that reason, both medications are contraindicated if you or a family member has had medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your prescribing provider will review your full history before recommending either one.

The dose schedule is there to keep side effects down. Semaglutide starts at 0.25 mg weekly, and tirzepatide starts at 2.5 mg weekly. Increasing the dose too fast is the main reason people feel unwell early on.

Which Patients Are Better Candidates?

Semaglutide suits people who want the option with the longer real-world safety record and cardiovascular outcome data. Tirzepatide suits people with larger weight-loss goals, people with type 2 diabetes who need dual metabolic control, and people who did not respond to GLP-1 therapy alone.

Semaglutide is a good fit for patients whose goal is moderate weight loss, and for patients with heart disease, since Wegovy is the one with an FDA-approved indication for lowering heart risk.

Tirzepatide is a good fit for patients with larger weight-loss goals, metabolic conditions such as insulin resistance or elevated fasting glucose, or too little response to semaglutide. The added GIP pathway may work for people who did not get enough of a result on GLP-1 therapy alone.

Some parts of your medical history matter for both. Neither is used during pregnancy, and the Wegovy label advises stopping semaglutide at least 2 months before a planned pregnancy. Tirzepatide can make birth control pills less reliable, so the Zepbound label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and after each dose increase. If you already did well on a GLP-1, switching to tirzepatide may not add much, and the people most likely to benefit from a switch are those who did not respond.

For weight management, Zepbound is approved for adults. Wegovy is approved for adults and for adolescents 12 and older. Both labels set the same starting point: a BMI of 30 or more, or 27 or more with a weight-related condition such as high blood pressure. There is less data for adults over 75, so individual assessment matters even more in that group.

At Original Glam Denver, Courtney Strocky, NP, conducts the necessary medical assessment at consultation before recommending either medication. Full details are on the medical weight loss program page.

What Do Clinical Trials Prove About Long-Term Efficacy?

The SURMOUNT (tirzepatide) and STEP (semaglutide) trial programs both show that results hold while people stay on treatment and that weight returns substantially after stopping. That is why both are considered long-term maintenance therapies, with no fixed end date.

The STEP 1 trial, published in the NEJM in 2021, followed 1,961 adults for 68 weeks. Average weight loss was 14.9% on semaglutide 2.4 mg and 2.4% on placebo. A follow-up withdrawal study found that participants who stopped semaglutide regained approximately two-thirds of the weight they had lost within one year.

The SURMOUNT-1 results, published in the NEJM in 2022, followed 2,539 adults for 72 weeks, with average weight loss of 15.0% to 20.9% depending on the dose. In the SURMOUNT-4 trial, people who had lost an average of 20.9% over 36 weeks on tirzepatide and then switched to placebo regained 14% of their body weight over the following year, while those who stayed on tirzepatide lost another 5.5%.

A retrospective observational study compared semaglutide and tirzepatide in 100 participants in Bangladesh, 58 on tirzepatide and 42 on semaglutide. Baseline BMI was higher in the tirzepatide group. Both groups lost weight, and tirzepatide produced greater reductions when combined with lifestyle changes.

Both medications improved blood pressure and lipid profiles as secondary outcomes. Semaglutide also reduced cardiovascular events in the SELECT trial in patients at high cardiovascular risk, which is meaningful evidence if your cardiac risk is elevated.

In recent trials, lean tissue made up roughly 26% to 40% of the weight lost on these medications, as a 2025 case series on preserving muscle summarizes. Resistance exercise is recommended on either medication to help preserve muscle during treatment.

How Should Medical Weight Loss Programs Integrate These Treatments?

Medication works best with nutrition and lifestyle support around it. In both the SURMOUNT and STEP trials, participants took the medication alongside a reduced-calorie diet and lifestyle counseling, so the published results already include that support. The American Diabetes Association's clinical guidelines recommend both medication classes as part of a comprehensive lifestyle program.

At Original Glam Denver, the medical weight loss program follows that evidence. It uses compounded semaglutide or tirzepatide. Compounded versions are not FDA-approved, and the trial results in this article were measured with the brand-name drugs, Wegovy and Zepbound. It includes a baseline clinical assessment, medication selection supervised by Courtney Strocky, NP, regular follow-ups to track your progress and adjust your dose, and health and mindset coaching throughout. If you are comparing Denver programs, our guide to medical weight loss in Denver covers what to ask before you enroll.

Baseline labs, required before you start, are a CBC, a comprehensive metabolic panel, a lipid panel, a thyroid panel and an A1C. The 16-week program includes weekly follow-ups with the nurse practitioner, virtual or in person, for the first month, then follow-ups every two weeks or monthly for the remaining three months.

Significant weight loss often brings up skin concerns such as laxity, texture changes, and shifts in body contour. Because Original Glam offers a full range of services, patients can add skin-tightening, body-contouring, and skin-quality treatments alongside their weight loss program.

The nutrition, exercise, and daily routines you build during treatment are the best protection against regain if you stop the medication.

What Are the Current Limitations and Emerging Developments?

The biggest limitation of both medications is the weight regain that follows stopping, so most patients use them long term. This reflects the chronic nature of obesity as a condition.

Both medications have strong safety data from the trial periods, and long-term post-market data is still coming in. Semaglutide has been used for diabetes since 2017, which gives it a longer real-world safety record than tirzepatide's more recent weight loss approval.

Trial data show these medications may reduce lean muscle along with fat. Resistance training throughout treatment is increasingly recommended as standard practice.

Retatrutide is an investigational medication that targets three receptors at once: GLP-1, GIP, and glucagon. Early results are promising, and it may become the next step beyond tirzepatide.

Frequently Asked Questions

Can I switch from semaglutide to tirzepatide if semaglutide is not working?

Yes. Switching is clinically appropriate if you have reached a therapeutic dose and not seen an adequate response after 4 to 6 months. Tirzepatide's dual GLP-1 and GIP mechanism may work for patients who did not get enough of a result on GLP-1 therapy alone. A switch needs a clinical reassessment and new baseline labs, and your prescribing provider should manage it.

Which medication is safer long-term?

Semaglutide has been in clinical use for type 2 diabetes since 2017 and for weight management since 2021, so its real-world safety record is longer. Tirzepatide's weight loss approval dates to November 2023, and post-market data is still accumulating. Both have favorable safety profiles in trials. Some patients reasonably weigh the longer track record against the newer efficacy data.

Do I need to diet if I am on semaglutide or tirzepatide?

Yes. The trial results, including the 14.9% loss in STEP 1 and up to 20.9% in SURMOUNT-1, came with reduced-calorie diets and lifestyle counseling. Either drug works better with structured nutrition guidance and regular physical activity than on its own. Original Glam's program includes this support throughout.

What happens if I stop taking semaglutide or tirzepatide?

Both medications need ongoing use to maintain results. Trial data after stopping show significant weight regain. In the STEP 1 extension, people regained about two-thirds of the weight they had lost within a year of stopping semaglutide. The habits you build during treatment are the best protection against regain when the medication is eventually reduced or stopped.

Can Original Glam Denver prescribe these medications?

Yes. Weight loss prescriptions at Original Glam Denver are written by Courtney Strocky, NP, a licensed nurse practitioner, and every medication decision follows a full clinical assessment.

Is tirzepatide's greater weight loss worth choosing it over semaglutide?

If your main goal is the most weight loss and you are a good candidate, tirzepatide's advantage is meaningful. If a longer safety record or your medical history points toward semaglutide, it may be the better choice. Your prescribing provider can help you decide based on your health profile.

Talk Through Semaglutide vs Tirzepatide at Original Glam

Either medication starts with a proper assessment. Courtney Strocky, NP, will review your history, run baseline labs, and build a supervised plan around your goals. Book your consultation here.

This article is for informational purposes only and does not constitute medical advice. Medical weight loss treatment should be assessed, prescribed, and supervised by a licensed medical provider.